Ryan Pearson, PhD, of the University of Maryland School of Pharmacy is moving forward with a unique approach to defeating sepsis using nanoparticles.
At the University of Maryland, Baltimore (UMB), groundbreaking discoveries happen every day — transforming medicine, improving health, and shaping the future. From changing legal policy to pioneering treatments to cutting-edge scientific breakthroughs, UMB researchers are tackling real-world challenges and making a lasting impact on lives everywhere.
In our “Breakthroughs Can’t Wait: Changing the Future Today” series of videos, we will dive into inspiring stories of innovation from across UMB’s seven schools. See how scientists, doctors, and experts are addressing today’s most pressing issues — fueled by the critical support of government funding that drives progress forward.
Sometimes the body responds to infection with an overreaction, casting a storm of life-threatening inflammation called sepsis.
Sepsis can lead to tissue damage and organ failure and is the leading cause of death in hospitals in the United States. But sepsis is also very complicated and presents with different symptoms in different patients. When diagnosed with sepsis, patients are often treated with antibiotics to fight the underlying infection while at the same time receiving fluids to stabilize organs and oxygen to improve breathing. Still, finding more effective tools to fight sepsis has proved to be very difficult.
Ryan Pearson, PhD, associate professor of pharmaceutical sciences and director of the Bio- and Nano-Technology Center at the University of Maryland School of Pharmacy, has been awarded a $3.4 million grant from the National Institutes of Health to move forward with a unique approach to defeating sepsis using nanoparticles. His approach is different because the custom-designed nanoparticles are not used to transport other drugs, but are themselves the treatment.
These drug-free nanoparticles are composed of biocompatible lactic and polylactic acid, which serve to change different aspects of a person’s immune response. In early tests, they’ve been shown to reduce pro-inflammatory responses without damaging key immune cells. They also work well with other antibiotics to improve the immune system’s ability to neutralize harmful bacteria causing infection.
Pearson’s interdisciplinary team includes co-principal investigator Lin Zou, MD, PhD, associate professor at the University of Maryland School of Medicine (UMSOM), and co-investigator Wei Chao, MD, PhD, FAHA, Anesthesiology Endowed Professor of Translational Research at UMSOM.
Watch the video below as Pearson talks about his work.